Sign in
Taking people in United StatesNo phase

Wearable sensor patch to spot early worsening in cardiogenic shock

Tests a wearable sensor patch in adults with cardiogenic shock.

Key facts

Who runs it
NIRSense Inc.
Where
Weston, United StatesSee the site
Trial code
Registry title
Clinical Evaluation of NIRSense Tissue Oximetry Sensor Monitoring to Early Detect Cardiogenic Shock
Status
Recruiting
People taking part
20 people, planned
Started
17 Jun 2025
Expected to end
Aug 2027
Type of study
Observational, 2 groups
Treatments tested
  • NIRSense Tissue Oximetry Sensor System
Record updated
17 September 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults in the cardiac intensive care unit with a heart attack or worsening heart failure who are in SCAI shock stage B, C, or D. They wear a sensor patch for about 24 to 72 hours.

Age
18 years or older
Sex
All sexes
Disease stage
Worsening heart failure with symptoms, or a heart attack with coronary angiography; admitted to intensive care in SCAI shock stage B, C, or D.

Main reasons for not taking part

  • Known severe allergy to medical adhesive or tape (self-reported)
  • Taking part in another drug or device study that would interfere with this one
  • Weight of 40 kg (88 lb) or less
  • The investigator thinks the person is not an appropriate candidate

The registry criteria, word for word

Show all 7 criteriaShow less

Who can take part

  • Acutely decompensated symptomatic heart failure (HF) documented by: (a) symptoms of HF requiring current treatment; (b) Society for Cardiovascular Angiography and Interventions (SCAI) stage B, C, or D; and (c) hospital admission with HF as the primary or secondary diagnosis; OR acute myocardial infarction (MI) patient undergoing coronary angiography
  • Admitted to the intensive care unit and currently in SCAI stage B, C, or D
  • Age 18 years or older
  • Weight greater than 40 kg

Who cannot take part

  • Prior known severe allergy to medical-grade adhesive or tape (self-reported)
  • Currently participating in an investigational drug or device study that would interfere with the conduct or results of this study. Trials requiring extended follow-up for products that were investigational but have since become commercially available are not considered investigational
  • The investigator believes the participant is not an appropriate candidate for the study

Where in United States

  • Cleveland Clinic Florida, Weston HospitalWeston, United StatesContact: David A. Baran, MDTaking people

About the trial

What the trial wants to find out

This is a prospective, single-center, observational pilot study of the investigational NIRSense Tissue Oximetry Sensor System (Envello Core), a noninvasive wearable sensor patch that uses near-infrared spectroscopy (NIRS) and photoplethysmography (PPG), combined with an electrocardiography/impedance cardiography (ECG/ICG) sensor, to continuously monitor tissue oxygen saturation (StO2), peripheral oxygen saturation (SpO2), pulse rate, respiratory rate, stroke volume, and related metrics. Up to 20 adults admitted to the Cleveland Clinic Florida cardiac intensive care unit with acute myocardial infarction or acute decompensated heart failure and in Society for Cardiovascular Angiography and Interventions (SCAI) shock stage B, C, or D will wear the sensors on the sternum, forearm, and other locations for approximately 24 to 72 hours during standard care. Sensor data will be compared with standard-of-care hemodynamic and laboratory measurements and with the patient's clinical course to evaluate the feasibility of the device, the correlation of its measurements with established clinical parameters, and its potential to detect deterioration in SCAI shock stage earlier. No treatment decisions are made based on the study device.

The 2 groups in the trial

  • Acute myocardial infarction

    Patients with acute myocardial infarction, with or without shock (SCAI stage B to D), admitted for coronary angiography and subsequent interventions. Enrolled at the time of consent for coronary angiography.

    Treatment: NIRSense Tissue Oximetry Sensor System

  • Acute decompensated heart failure

    Patients with acute decompensated heart failure (SCAI stage B to D) admitted for pulmonary artery catheter insertion and subsequent interventions. Consented before or after catheterization.

    Treatment: NIRSense Tissue Oximetry Sensor System

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Clinical Evaluation of Using NIRSense Sensor Patch to Measure Microvascular Perfusion Responses and Predict Decompensation in Cardiogenic Shock Patients
Plain-language title
Wearable sensor patch to spot early worsening in cardiogenic shockGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Record updated
17 September 2026